2003
DOI: 10.1016/s0264-410x(02)00746-6
|View full text |Cite
|
Sign up to set email alerts
|

Red blood cell-mediated delivery of recombinant HIV-1 Tat protein in mice induces anti-Tat neutralizing antibodies and CTL

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
24
0
2

Year Published

2005
2005
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 43 publications
(26 citation statements)
references
References 64 publications
0
24
0
2
Order By: Relevance
“…Of these, biotinylation of TNF-α was proposed as an approach to direct the cytokine to the membrane of melanoma cells [17], and biotinylation of red blood cells as a potential antigen delivery system via the biotin-avidin-biotin bridge [18]. An interesting report demonstrates the safety and specificity of red blood cell delivery of HIV-Tat as a step in the design of a new anti-HIV vaccine [19]. To tweak our technique, we first performed biotin labeling of MSC membrane proteins with the biotinylating agent sulfo-NHS-biotin reagents (Fig.…”
Section: Discussionmentioning
confidence: 99%
“…Of these, biotinylation of TNF-α was proposed as an approach to direct the cytokine to the membrane of melanoma cells [17], and biotinylation of red blood cells as a potential antigen delivery system via the biotin-avidin-biotin bridge [18]. An interesting report demonstrates the safety and specificity of red blood cell delivery of HIV-Tat as a step in the design of a new anti-HIV vaccine [19]. To tweak our technique, we first performed biotin labeling of MSC membrane proteins with the biotinylating agent sulfo-NHS-biotin reagents (Fig.…”
Section: Discussionmentioning
confidence: 99%
“…Nevertheless, due to the possible side effects of Tat (14,53,69,70,72), administration of active Tat to patients might pose serious safety concerns. Chemically modified Tat-based vaccines have been proposed as an attractive option (18,52,67). However, immunization of macaques with Tat toxoid concomitantly with an adjuvant only attenuated disease (52).…”
Section: Discussionmentioning
confidence: 99%
“…We have examined the ability of three Aβ-degrading enzymes, neprilysin (NEP) [16], insulysin (IDE) [36], and metalloprotease-1 (MP-1) [12] coupled to erythrocytes to degrade Aβ both in vitro and in vivo. Expression of Aβ-degrading enzymes in the periphery represents a novel way to lower plasma Aβlevels by hydrolytic cleavage rather than by forming Aβ complexes, and the use of erythrocyte coupling as a drug delivery system has been shown to be a promising therapeutic avenue [9,26,33]. Although brain expression of Aβ-degrading enzymes as a way to lower brain Aβ levels has been used successfully in a number of studies [15,18,22,29] peripheral expression has not been explored to any great extent.…”
Section: Introductionmentioning
confidence: 99%